DaVita (FRA:TRL) Equivalent Admissions #: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TRL DaVita Inc FRA:TRL
86 GF Score
Price €206.20
GF Value €152.92
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is DaVita Equivalent Admissions #?

DaVita FRA:TRL +1.63% 86 Equivalent Admissions # is 0.00 as of . 20. GuruFocus rates FRA:TRL with a GF Score™ of 86/100 and a GF Value™ of €152.92 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Equivalent Admissions # are a general measure used to indicate combined inpatient and outpatient volumes.

The historical rank and industry rank for DaVita's Equivalent Admissions # or its related term are showing as below:

FRA:TRL's Equivalent Admissions # is not ranked *
in the Healthcare Providers & Services industry.
Industry Median:
* Ranked among companies with meaningful Equivalent Admissions # only.

DaVita Equivalent Admissions # Historical Data

* Premium members only.

The historical data trend for DaVita's Equivalent Admissions # can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DaVita Equivalent Admissions # Chart


FRA:TRL
86GF Score
DaVita Inc FRA:TRL
Equivalent Admissions # is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions
What does a Equivalent Admissions # of 0.00 mean?
DaVita (FRA:TRL) has a Equivalent Admissions # of 0.00 as of . 20. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on DaVita and its competitors.
Is DaVita's Equivalent Admissions # too high?
DaVita's current Equivalent Admissions # is 0.00. Overall, DaVita has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DaVita's Equivalent Admissions # compare to THC and EHC?
DaVita's Equivalent Admissions # of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equivalent Admissions # for a Healthcare Providers & Services company?
A good Equivalent Admissions # depends on the Healthcare Providers & Services industry context. However, Equivalent Admissions # should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equivalent Admissions # mean?
A high Equivalent Admissions # can signal that a stock is expensive relative to its fundamentals. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on DaVita and its competitors. DaVita's current Equivalent Admissions # is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (FRA:TRL) is currently considered Significantly Overvalued. The stock's GF Value™ is €152.92, compared to a current price of €206.20 — trading 34.8% above its estimated fair value. The current Equivalent Admissions # is 0.00. DaVita's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equivalent Admissions # calculated?
Equivalent Admissions # is calculated from a company's financial statements. For DaVita (FRA:TRL), the current Equivalent Admissions # is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DaVita (FRA:TRL) Overvalued in 2026?

Based on GuruFocus' analysis, DaVita stock appears to be overvalued. The current stock price of €206.20 is trading 34.8% above its estimated GF Value™ of €152.92. GuruFocus considers DaVita to be Significantly Overvalued.

Key valuation signals for FRA:TRL:

  • Equivalent Admissions #: 0.00
  • GF Value™: €152.92 vs. price of €206.20 (34.8% above fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the FRA:TRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaVita Business Description

Address 2000 16th Street, Denver, CO, USA, 80202
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
86GF Score

Get the complete analysis for FRA:TRL

Equivalent Admissions # is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€206.20
Price
€152.92
GF Value